JP2017524734A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524734A5
JP2017524734A5 JP2017521031A JP2017521031A JP2017524734A5 JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5 JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017521031 A JP2017521031 A JP 2017521031A JP 2017524734 A5 JP2017524734 A5 JP 2017524734A5
Authority
JP
Japan
Prior art keywords
amino
methyl
carbonyl
thienyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017521031A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524734A (ja
JP6603712B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038712 external-priority patent/WO2016004136A1/en
Publication of JP2017524734A publication Critical patent/JP2017524734A/ja
Publication of JP2017524734A5 publication Critical patent/JP2017524734A5/ja
Application granted granted Critical
Publication of JP6603712B2 publication Critical patent/JP6603712B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017521031A 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物 Active JP6603712B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462019756P 2014-07-01 2014-07-01
US62/019,756 2014-07-01
US201562185678P 2015-06-28 2015-06-28
US62/185,678 2015-06-28
PCT/US2015/038712 WO2016004136A1 (en) 2014-07-01 2015-06-30 Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019187426A Division JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Publications (3)

Publication Number Publication Date
JP2017524734A JP2017524734A (ja) 2017-08-31
JP2017524734A5 true JP2017524734A5 (cg-RX-API-DMAC7.html) 2019-07-11
JP6603712B2 JP6603712B2 (ja) 2019-11-06

Family

ID=55019950

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017521031A Active JP6603712B2 (ja) 2014-07-01 2015-06-30 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019187426A Withdrawn JP2020023538A (ja) 2014-07-01 2019-10-11 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2021131914A Pending JP2021178869A (ja) 2014-07-01 2021-08-13 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物
JP2023191459A Withdrawn JP2024012558A (ja) 2014-07-01 2023-11-09 Sumo活性化酵素の阻害薬として有用なヘテロアリール化合物

Country Status (39)

Country Link
US (6) US9683003B2 (cg-RX-API-DMAC7.html)
EP (3) EP3517112B1 (cg-RX-API-DMAC7.html)
JP (4) JP6603712B2 (cg-RX-API-DMAC7.html)
KR (1) KR102491125B1 (cg-RX-API-DMAC7.html)
CN (1) CN106999479B (cg-RX-API-DMAC7.html)
AU (1) AU2015284135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016030787B1 (cg-RX-API-DMAC7.html)
CA (1) CA2953132C (cg-RX-API-DMAC7.html)
CL (1) CL2016003398A1 (cg-RX-API-DMAC7.html)
CR (1) CR20170021A (cg-RX-API-DMAC7.html)
CY (1) CY1122808T1 (cg-RX-API-DMAC7.html)
DK (1) DK3164130T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2016000339A (cg-RX-API-DMAC7.html)
EA (1) EA034119B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17006751A (cg-RX-API-DMAC7.html)
ES (1) ES2754359T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20197047B (cg-RX-API-DMAC7.html)
HR (1) HRP20191979T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045748T2 (cg-RX-API-DMAC7.html)
IL (1) IL249820B (cg-RX-API-DMAC7.html)
LT (1) LT3164130T (cg-RX-API-DMAC7.html)
ME (1) ME03574B (cg-RX-API-DMAC7.html)
MX (1) MX376054B (cg-RX-API-DMAC7.html)
MY (1) MY183649A (cg-RX-API-DMAC7.html)
NZ (1) NZ728162A (cg-RX-API-DMAC7.html)
PE (1) PE20170520A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016502595B1 (cg-RX-API-DMAC7.html)
PL (1) PL3164130T3 (cg-RX-API-DMAC7.html)
PT (1) PT3164130T (cg-RX-API-DMAC7.html)
RS (1) RS59474B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201610476VA (cg-RX-API-DMAC7.html)
SI (1) SI3164130T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900600T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000581A1 (cg-RX-API-DMAC7.html)
TW (1) TWI680970B (cg-RX-API-DMAC7.html)
UA (1) UA122963C2 (cg-RX-API-DMAC7.html)
UY (1) UY36198A (cg-RX-API-DMAC7.html)
WO (1) WO2016004136A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700386B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1201817A1 (en) 2012-02-17 2015-09-11 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
HRP20191979T1 (hr) 2014-07-01 2020-02-07 Millennium Pharmaceuticals, Inc. Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima
US10465447B2 (en) 2015-03-12 2019-11-05 Baker Hughes, A Ge Company, Llc Cutting elements configured to mitigate diamond table failure, earth-boring tools including such cutting elements, and related methods
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
KR102531344B1 (ko) 2016-10-03 2023-05-10 얀센 파마슈티카 엔.브이. Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
JP7225106B2 (ja) 2017-02-27 2023-02-20 ヤンセン ファーマシューティカ エヌ.ベー. Prmt5阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
US10400517B2 (en) 2017-05-02 2019-09-03 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and related tools and methods
EP3684363A4 (en) 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
JP7352544B2 (ja) 2017-12-08 2023-09-28 ヤンセン ファーマシューティカ エヌ.ベー. 新規なスピロ二環式類似体
US20210015915A1 (en) 2018-03-23 2021-01-21 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
BR112021000169A2 (pt) * 2018-07-09 2021-04-06 Millennium Pharmaceuticals, Inc. Ministração de inibidor de enzima ativadora de sumo e anticorpos anti-cd20
US10570668B2 (en) 2018-07-27 2020-02-25 Baker Hughes, A Ge Company, Llc Cutting elements configured to reduce impact damage and mitigate polycrystalline, superabrasive material failure earth-boring tools including such cutting elements, and related methods
CN109354569A (zh) * 2018-11-27 2019-02-19 常州大学 一种1,3-二溴-4-氟苯的制备方法
EP3930720A4 (en) * 2019-02-26 2022-12-28 Millennium Pharmaceuticals, Inc. COMPOUNDS USEFUL AS ADJUVANTS
BR112021016795A8 (pt) * 2019-02-27 2022-08-16 Millennium Pharm Inc Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用prmt5抑制劑治療癌症之方法
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112402608B (zh) * 2020-11-30 2021-09-07 深圳先进技术研究院 5-烷氧基吲哚-3-乙烯基喹啉盐作为靶向可迁移光敏剂的应用
WO2021203001A1 (en) * 2020-04-03 2021-10-07 Millennium Pharmaceuticals, Inc. Method of treating patients infected with a viral infection with an inhibitor of small ubiquitin like modifier activating enzyme
TW202207935A (zh) * 2020-05-15 2022-03-01 美商千禧製藥公司 Sumo活化酶抑制劑及抗cd38抗體之投與
CN116917594A (zh) 2021-02-05 2023-10-20 贝克休斯油田作业有限责任公司 钻地工具的切割元件以及制造钻地工具的方法
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法
WO2023073645A1 (en) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
US11920409B2 (en) 2022-07-05 2024-03-05 Baker Hughes Oilfield Operations Llc Cutting elements, earth-boring tools including the cutting elements, and methods of forming the earth-boring tools
EP4596557A1 (en) 2022-09-30 2025-08-06 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Compound as inhibitor for sumo activating enzyme
WO2024099438A1 (zh) * 2022-11-11 2024-05-16 微境生物医药科技(上海)有限公司 作为sumo活化酶抑制剂的化合物
WO2024110863A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited Process and intermediates for preparing ((1r,2s,4r)-4-((5-(4-((r)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-methylthiophene-2-carbonyl)pyrimidin-4-yl)amino)-2-hydroxycyclopentyl)methyl sulfamate
CN117209449B (zh) * 2023-09-14 2025-11-28 上海毕得医药科技股份有限公司 一种2-(三氟甲基)噻唑类化合物的合成方法
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
CN119371416B (zh) * 2024-12-23 2025-05-30 上海达歌生物医药科技有限公司 一种通过氧杂环丁烷开环以构建4-取代异香豆素及其类似物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
CA2477795A1 (en) 2002-02-28 2003-09-12 Kandasamy Sakthivel Nucleoside 5'-monophosphate mimics and their prodrugs
CA2481855A1 (en) * 2002-04-10 2003-10-23 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
US7527966B2 (en) 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2004009610A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
ES2283868T3 (es) 2002-09-04 2007-11-01 Schering Corporation Compuestos pirazol(1,5-a) pirimidina como inhibidores de quinasa dependiente de ciclina.
CN1310918C (zh) 2002-09-04 2007-04-18 先灵公司 作为细胞周期蛋白依赖激酶抑制剂的吡唑并嘧啶
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ[1,5−a]ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
WO2005037845A1 (en) 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
WO2005051949A1 (ja) 2003-11-26 2005-06-09 Dainippon Sumitomo Pharma Co., Ltd. 新規縮合イミダゾール誘導体
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ユビキチンリガーゼ阻害剤
EP1848718B1 (en) 2005-02-04 2012-08-01 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
MY171289A (en) 2006-02-02 2019-10-07 Millennium Pharm Inc Inhibitors of e1 activating enzymes
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
JP5274460B2 (ja) * 2006-08-08 2013-08-28 ミレニアム ファーマシューティカルズ, インコーポレイテッド E1活性化酵素のインヒビターとして有用なヘテロアリール化合物
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
WO2009042013A1 (en) 2007-08-02 2009-04-02 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8962580B2 (en) 2008-09-23 2015-02-24 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
NZ596470A (en) 2009-05-14 2014-04-30 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
CN108752280A (zh) 2009-08-17 2018-11-06 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011100131A2 (en) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2542081A4 (en) 2010-03-01 2013-07-31 Gtx Inc COMPOSITIONS FOR CANCER TREATMENT
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
EP2748168A4 (en) 2011-08-24 2015-04-22 Millennium Pharm Inc HEMMER OF NEDD8-ACTIVATING ENZYME
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
HK1201817A1 (en) * 2012-02-17 2015-09-11 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
BR112015032902A8 (pt) * 2013-07-02 2019-12-24 Millennium Pharm Inc compostos de heteroarila, seus usos e composições farmacêuticas
WO2015048547A2 (en) 2013-09-26 2015-04-02 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
RS59140B1 (sr) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
HRP20191979T1 (hr) 2014-07-01 2020-02-07 Millennium Pharmaceuticals, Inc. Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima

Similar Documents

Publication Publication Date Title
JP2017524734A5 (cg-RX-API-DMAC7.html)
CN115605476B (zh) 取代的三环化合物
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
KR101750667B1 (ko) Syk 억제제
KR101903925B1 (ko) 헤테로아릴 화합물의 합성 및 정제 방법
DE60304718T2 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
JP5232841B2 (ja) N4−フェニルキナゾリン−4−アミン誘導体の製造方法およびその中間体
JP6306049B2 (ja) A2aアンタゴニスト特性を有するヘテロビシクロ−置換−[1,2,4]トリアゾロ[1,5−c]キナゾリン−5−アミン化合物
KR20210099611A (ko) 헤테로 방향족 유도체 조절제, 이의 제조방법 및 용도
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
CN114539245A (zh) 含嘧啶并环类衍生物调节剂、其制备方法和应用
WO2015171527A1 (en) Pyrazolopyridine pyrazolopyrimidine and related compounds
AU2004210855A1 (en) Pyrazoles and methods of making and using the same
JP2005526029A (ja) 細胞増殖が関与する疾患を治療するためのキノリノン誘導体
KR20110039307A (ko) 이미다조피리딘-2-온 유도체
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
JP2022502424A (ja) モノアシルグリセロールリパーゼ調節因子
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
HU204273B (en) Process fo producing triazolo-benzo- and thieno-triazolo-diazepines and pharmaceutical compositions containing them
RU2019108717A (ru) Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
WO2022167682A1 (en) Azabicyclic shp2 inhibitors
AU2010334591C1 (en) Inhibitors of AKT activity
CA2723279A1 (en) 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
Shiryaev et al. Synthesis of 5 H-thiazolo [3, 2-a] pyrimidines